 we report on our first quarter 2019 financial results including net revenues of $3.7 million and net sales of common warts solution for the treatment of common warts verruca vulgaris or common warts. 
 we have completed enrollment of over 1000 patients in our two pivotal clinical trials named THART-1 and THART-2 for the treatment of common warts and we expect to report on the second half of 2019 results from both of these studies. 
 we also report on the status of our ongoing clinical development programs for the treatment of alopecia areata, both the milder and severe forms, androgenetic alopecia, also known as male/female pattern baldness, atopic dermatitis and vitiligo and also for the treatment of common warts.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 